Compare Pfizer with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs GLENMARK PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER GLENMARK PHARMA PFIZER/
GLENMARK PHARMA
 
P/E (TTM) x 36.3 12.1 300.0% View Chart
P/BV x 6.1 1.7 354.3% View Chart
Dividend Yield % 0.6 0.6 95.8%  

Financials

 PFIZER   GLENMARK PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-19
GLENMARK PHARMA
Mar-19
PFIZER/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,840712 539.6%   
Low Rs2,080484 430.1%   
Sales per share (Unadj.) Rs455.0349.6 130.1%  
Earnings per share (Unadj.) Rs93.832.8 286.1%  
Cash flow per share (Unadj.) Rs109.444.3 246.7%  
Dividends per share (Unadj.) Rs22.502.00 1,125.0%  
Dividend yield (eoy) %0.80.3 227.1%  
Book value per share (Unadj.) Rs658.2198.6 331.4%  
Shares outstanding (eoy) m45.75282.17 16.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.51.7 380.6%   
Avg P/E ratio x31.618.2 173.1%  
P/CF ratio (eoy) x27.113.5 200.7%  
Price / Book Value ratio x4.53.0 149.5%  
Dividend payout %24.06.1 393.2%   
Avg Mkt Cap Rs m135,420168,625 80.3%   
No. of employees `0002.612.0 21.9%   
Total wages/salary Rs m3,23820,561 15.8%   
Avg. sales/employee Rs Th7,911.48,196.0 96.5%   
Avg. wages/employee Rs Th1,230.91,708.1 72.1%   
Avg. net profit/employee Rs Th1,630.7768.5 212.2%   
INCOME DATA
Net Sales Rs m20,81598,655 21.1%  
Other income Rs m1,6742,081 80.4%   
Total revenues Rs m22,489100,736 22.3%   
Gross profit Rs m5,71215,858 36.0%  
Depreciation Rs m7143,259 21.9%   
Interest Rs m733,346 2.2%   
Profit before tax Rs m6,59911,335 58.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,3093,756 61.5%   
Profit after tax Rs m4,2919,250 46.4%  
Gross profit margin %27.416.1 170.7%  
Effective tax rate %35.033.1 105.6%   
Net profit margin %20.69.4 219.8%  
BALANCE SHEET DATA
Current assets Rs m27,16766,968 40.6%   
Current liabilities Rs m8,91740,211 22.2%   
Net working cap to sales %87.727.1 323.3%  
Current ratio x3.01.7 182.9%  
Inventory Days Days6883 81.4%  
Debtors Days Days3081 37.1%  
Net fixed assets Rs m8,86233,322 26.6%   
Share capital Rs m458282 162.1%   
"Free" reserves Rs m29,65655,770 53.2%   
Net worth Rs m30,11356,052 53.7%   
Long term debt Rs m2535,738 0.1%   
Total assets Rs m39,400132,888 29.6%  
Interest coverage x91.54.4 2,085.9%   
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x0.50.7 71.2%   
Return on assets %11.19.5 116.8%  
Return on equity %14.216.5 86.3%  
Return on capital %22.117.8 124.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42862,998 0.7%   
Fx outflow Rs m78622,859 3.4%   
Net fx Rs m-35840,140 -0.9%   
CASH FLOW
From Operations Rs m97813,242 7.4%  
From Investments Rs m351-6,990 -5.0%  
From Financial Activity Rs m-1,099-7,387 14.9%  
Net Cashflow Rs m231-2,971 -7.8%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 4.9 34.4 14.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 56,727 150.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   FULFORD INDIA  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare PFIZER With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Why is Sensex at a Record High When Economy is in Trouble?(Podcast)

In today's episode, I talk about all the major moves of the week, including Modi government's blockbuster disinvestment, developments in the telecom sector.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Nov 22, 2019 | Updated on Nov 22, 2019

PFIZER share price has hit an all time high at Rs 4,199 (up 1.7%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 1.7%) and ABBOTT INDIA (up 0.6%). The top losers include DR. REDDYS LAB (down 0.1%) and ALKEM LABORATORIES (down 0.3%).

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Nov 22, 2019 | Updated on Nov 22, 2019

PFIZER share price has hit an all time high at Rs 4,189 (up 0.6%). The BSE HEALTHCARE Index is up by 0.3%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 0.6%) and SANOFI INDIA (up 0.4%). The top losers include CADILA HEALTHCARE (down 0.1%) and GSK PHARMA (down 0.2%).

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 22, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS